Detalhe da pesquisa
1.
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.
Oncologist
; 28(7): 565-574, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37210568
2.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Breast Cancer Res
; 22(1): 120, 2020 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33138866
3.
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.
Eur J Cancer
; 201: 113920, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38368741
4.
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer.
J Exp Med
; 220(4)2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36688919
5.
Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer.
Mol Cancer Ther
; 22(11): 1304-1318, 2023 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37676980
6.
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer.
NPJ Breast Cancer
; 9(1): 50, 2023 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37268625
7.
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.
Nat Commun
; 14(1): 7496, 2023 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37980405
8.
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.
Nat Cancer
; 4(1): 128-147, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36585450
9.
Understanding resistance to immune checkpoint inhibitors in advanced breast cancer.
Expert Rev Anticancer Ther
; 22(2): 141-153, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34919490
10.
Emerging Targeted Therapies for Early Breast Cancer.
Drugs
; 82(14): 1437-1451, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36207645
11.
Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer.
Am J Clin Oncol
; 44(9): 449-455, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34149037
12.
Genomic Characterization of de novo Metastatic Breast Cancer.
Clin Cancer Res
; 27(4): 1105-1118, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33293374
13.
Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing.
JCO Precis Oncol
; 4: 1084-1097, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35050773
14.
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.
Clin Cancer Res
; 26(11): 2565-2572, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32019858
15.
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
Clin Cancer Res
; 26(21): 5668-5681, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32826327
16.
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.
Cancer Discov
; 9(2): 176-198, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30679171
17.
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.
JCO Precis Oncol
; 32019.
Artigo
em Inglês
| MEDLINE | ID: mdl-32923853
18.
Correction: PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer.
J Exp Med
; 220(9)2023 Sep 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37615687
19.
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
JAMA Oncol
; 4(2): 173-182, 2018 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28973656
20.
Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer.
Cancer Res
; 78(18): 5300-5314, 2018 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30065048